IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration.

The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of hypertension. Next-step development is scheduled to initiate soon .

SAN FRANCISCO and SUZHOU, China , Nov. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, jointly announced with Sanegene Bio USA Inc. (SanegeneBio), a global clinical-stage biotechnology comp

See Full Page